The Crossover Study

Currently Recruiting

17 Nov 2025 to 11 Dec 2025

Up to $5,470

We’re conducting a clinical trial to compare two formulations of a potential new treatment, Asengeprast, in healthy adult volunteers. This treatment is being developed for future use in conditions involving inflammation and fibrosis, such as chronic kidney disease and Systemic Sclerosis (a connective tissue disorder that can cause fibrosis (thickening) to the skin and internal organs). 

Apply now Speak with us

Join our clinical trial

We’re conducting a clinical trial to compare two formulations of a potential new treatment, Asengeprast, in healthy adult volunteers. This treatment is being developed for future use in conditions involving inflammation and fibrosis, such as chronic kidney disease and Systemic Sclerosis (a connective tissue disorder that can cause fibrosis (thickening) to the skin and internal organs).

Asengeprast FA has already been administered to patients in Phase I and II trials, demonstrating its safety in clinical settings. On the other hand, Asengeprast MEA is currently in its First-In-Human (FIH) phase, meaning it is now being evaluated in humans for the first time. 

The goal of this study is to understand how the body absorbs and processes each version of Asengerprast, and to assess their safety and tolerability.

Nucleus Network - Image

Why participate?

As a participant, you’ll receive the study medication and undergo assessments to monitor how your body responds. Your involvement will provide essential data that can help guide future research. 

  • Contribute to research that may support the development of new treatment options.
  • Help researchers better understand how this investigational drug behaves in the body.
  • Receive thorough health assessments and medical oversight throughout the study.

Trial details

Study medication

Administered via oral capsule.

Ethics

An independent ethics committee has approved this clinical trial. 

Additional eligibility

  • Body weight ≥50 kg for males and ≥47 kg for females 
  • No significant medical history 
  • Not taking any prescription medication (except for contraception) 
  • Non-smoker or smoking 5 or less cigarettes per day 

Study duration

3 x 3-night in-clinic stays and 1 follow-up visit

Are you a match?

Age

18 - 65 years old

Remuneration

Up to $5,470 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

9 nights, 1 clinic visit

Register Your Interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact